Concepedia

Publication | Closed Access

JUMP-C: A Randomized Trial of Mericitabine Plus Pegylated Interferon Alpha-2a/Ribavirin for 24 Weeks in Treatment-NaÏVe HCV Genotype 1/4 Patients

DOI

53

Citations

16

References

2013

Year

Paul J. Pockros, Donald M. Jensen, Naoky Tsai, Ryan M. Taylor, Alnoor Ramji, Curtis Cooper, Rolland C. Dickson, Alan D. Tice, Rohit Kulkarni, John M. Vierling,
Hepatology

Abstract

A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNα-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNα-2a/RBV.

References

YearCitations

Page 1